Twenty-four-week data from the Ph1/2a trial in glaucoma patients reveals PER-001 to be well-tolerated. Proof of concept is established with both strong functional and structural outcomes Glaucoma patients treated with PER-001 on top of IOP reducing therapies experienced a mean improvement…

NASHVILLE, Tenn., March 3, 2025 /PRNewswire/ — Brookdale Senior Living Inc. (NYSE: BKD) (“Brookdale” or the “Company”) today announced the February 27, 2025 closing of two portfolio acquisitions, completing its three-portfolio acquisition plan initially announced in September 2024….

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.